Subpotent Antibiotic Pulled

Lupin Pharmaceuticals Inc. is recalling 26,352 bottles of rifampin capsules because the drug is subpotent, according to the April 17, 2024, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects rifampin capsules, 300 mg, in 30-count bottles (NDC 68180-659-06), from lot A201064 (Exp. 3/24). The capsules were manufactured for Lupin Pharmaceuticals, Baltimore, Maryland, by Lupin Limited, Aurangabad, India, and were distributed throughout the United States.

Lupin Pharmaceuticals voluntarily initiated the recall March 21, 2024. On April 5, 2024, the FDA designated the recall a Class II. Per the designation, use of the affected capsules could cause temporary or medically reversible adverse health consequences, or a remote possibility of serious harm.

Rifampin is a prescription antibiotic indicated in the treatment of tuberculosis and meningococcal carrier state.